BioMarin Pharmaceutical/ US09061G1013 /
| 6/14/2021 9:59:54 PM | Chg. +0.39 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 82.46USD | +0.48% | 16,979 Turnover: 1.4 mill. |
-Bid Size: - | -Ask Size: - | 15.07 bill.USD | 0.00% | 17.36 |
Fundamentals
| FY 2020 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 4.75 USD | - |
| EPS Diluted: | 4.53 USD | - |
| Revenues per Share: | 10.24 USD | 8.04% |
| Book Value per Share: | 22.59 USD | 30.12% |
| Cash Flow per Share: | 0.47 USD | 74.96% |
| Dividend per Share: | 0.00 USD | - |
| Total | in mill. | |
| Revenues: | 1,860.50 USD | 9.18% |
| Net Income: | 859.10 USD | - |
| Operating Cash Flow: | 85.40 USD | - |
| Cash and Cash Equivalents: | 649.20 USD | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | 17.36 | 18.46 |
| P/S Ratio: | 8.06 | 8.57 |
| P/BV ratio: | 3.65 | 3.88 |
| P/CF Ratio: | 175.53 | 186.61 |
| PEG: | - | - |
| Earnings Yield: | 5.76% | 5.42% |
| Dividend Yield: | 0.00% | 0.00% |
| Market Capitalization | ||
| Market Capitalization: | 15.07 bill. USD | 15.94 bill. USD |
| Free Float Market Cap.: | 8.33 bill. USD | 8.81 bill. USD |
| Market Cap. / Employee: | 4.9 mill. USD | 5.21 mill. USD |
| Shares Outstanding: | 182.74 mill. | |
Profitability
| Gross Profit Margin: | 100.00% |
| EBIT Margin: | -1.98% |
| Net Profit Margin: | 46.18% |
| Return on Equity: | 20.92% |
| Return on Assets: | 14.69% |
Financial Strength
| Liquidity I / Cash Ratio: | 131.82% |
| Liquidity II / Quick Ratio: | 131.82% |
| Liquidity III / Current Ratio: | 475.57% |
| Debt / Equity Ratio: | 42.43% |
| Dynam. Debt / Equity Ratio: | 2,039.81% |
Efficiency
| Employees: | 3,059 |
| Personal Expenses / Employee: | - USD |
| Revenues / Employee: | 608,205.30 USD |
| Net Income / Employee: | 280,843.41 USD |
| Total Assets / Employee: | 1,911,735.86 USD |
| * Fiscal Year End: | 12/31/2020 |
| Accounting Standard: | US GAAP |
| Currency: | USD |